Olanzapine
In brief
- Olanzapine is a prescription-only medicine in the UK and most countries; it is supplied via pharmacies, hospitals and licensed wholesalers (original brands such as Zyprexa® and many generics are widely available). Some online sellers or unregulated sources may offer it without a prescription, but legal supply should always follow local prescription requirements and supervised medical care.
- Olanzapine is used for schizophrenia, bipolar I disorder (mania and maintenance) and acute agitation; it is an atypical antipsychotic that mainly antagonises dopamine D2 and serotonin 5‑HT2A receptors (with additional antihistaminic, antimuscarinic and alpha‑adrenergic actions contributing to both therapeutic effects and side effects).
- Typical adult oral doses: schizophrenia often starts at 5–10 mg daily (usual range 5–20 mg/day, maximum 20 mg/day); bipolar disorder commonly 10–15 mg daily; for acute agitation an intramuscular 10 mg dose is used (cumulative limits apply—generally not to exceed 30 mg in 24 hours). Doses are individualised and titrated, often in 5 mg steps.
- Forms of administration include oral tablets (2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg), orally disintegrating tablets (ODTs, various strengths) and intramuscular injection for acute agitation.
- Onset: sedative and calming effects may be noticed within 1–4 hours after an oral dose (IM routes act faster), while meaningful antipsychotic improvement for symptoms of psychosis typically develops over days to weeks.
- Duration of action: olanzapine is usually dosed once daily with clinical effects lasting 24 hours for maintenance dosing; the drug has a relatively long elimination half‑life (variable, generally measured in tens of hours), while IM formulations provide shorter‑term control of acute agitation.
- Alcohol warning: avoid alcohol while taking olanzapine because it increases sedation, impairs coordination and can exacerbate respiratory depression and other adverse effects.
- The most common side effect is weight gain; other frequent effects include drowsiness/sedation, dizziness, increased appetite, metabolic changes (raised glucose and lipids), dry mouth and constipation.
- Would you like to try “olanzapine” without a prescription?
Market Realities And Patient Experiences With Olanzapine
Basic Olanzapine Information
- INN (International Nonproprietary Name): Olanzapine
- Brand Names Available In United Kingdom: Zyprexa®, Olanzapine Actavis, Olanzapine Glenmark, Olanzapine Cipla, Olanzapine ODT and other generics (availability varies by supplier)
- ATC Code: N05AH03
- Forms & Dosages: Tablets 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg; Orally Disintegrating Tablets (ODTs) 5 mg, 10 mg, 15 mg (varies by supplier); Intramuscular injection for acute agitation (brand-specific packaging)
- Manufacturers In United Kingdom: not specified
- Registration Status In United Kingdom: Prescription only (Rx); widely registered in major markets per manufacturer listings
- OTC / Rx Classification: Prescription only (Rx)
Availability, Demand And Patient-Reported Outcomes
Olanzapine is a widely used atypical antipsychotic in both inpatient and community psychiatry.
Pharmacies routinely dispense repeat prescriptions for schizophrenia and bipolar I maintenance and acute relapse prevention.
High demand often produces frequent patient questions about side effects such as weight gain and sedation, which in practice affect adherence.
Patients commonly report strong benefit for positive symptoms, including reduced hallucinations and delusions, alongside frustration about metabolic changes and dose-related drowsiness.
Clinicians and pharmacists see brand preference for orally disintegrating formulations when swallowing difficulty is present.
Seasonal stock pressures and weekend supply gaps cause last-minute pharmacy visits, especially on Fridays.
Adherence issues fall under the umbrella of antipsychotic adherence and often require joint GP, specialist and pharmacy interventions.
Pharmacists note repeat dispensing patterns and the importance of consistent counselling to maintain long-term adherence.
Clear communication about metabolic side effects and practical mitigation measures helps retain patients on effective doses.
Real-World Retail Behaviours And Online Buying
How do patients actually get olanzapine in the UK?
NHS repeat prescribing remains the dominant route for community patients, with electronic prescription services smoothing collection from local chemists.
Private prescriptions and a rising number of online pharmacies give patients additional choice on price, brand and convenience.
Major retail chains and online providers—Boots, LloydsPharmacy, Superdrug and several independent online chemists—affect purchasing decisions through availability and delivery options.
Scottish patients often benefit from free prescriptions, which changes cost-driven behaviour compared with patients in England.
Pharmacist consultations, whether in person or via online platforms, act as important clinical touchpoints for reviewing interactions and monitoring.
Electronic prescriptions reduce dispensing errors and speed turnaround, particularly for stable patients on olanzapine tablets or ODTs.
Visual checkout flows and a short counselling checklist improve safety and conversion for online pharmacies offering olanzapine products.
Product Overview — Formulations, Brands And Regulatory Identity
INN, ATC And Core Product Forms
What is olanzapine in regulatory and formulation terms?
The International Nonproprietary Name (INN) is olanzapine and the ATC code is N05AH03.
Common pharmaceutical forms available include tablets in strengths from 2.5 mg to 20 mg, orally disintegrating tablets (ODTs) typically in 5 mg, 10 mg and 15 mg strengths, and intramuscular (IM) injections for acute agitation.
Tablets are the most commonly dispensed community formulation; ODTs are selected for patients with swallowing difficulties or where supervised administration is required.
IM formulations are used mainly in emergency or inpatient settings for rapid control of agitation.
Brands, Manufacturers And Regulatory Status
The market contains both originator and multiple generic suppliers.
Zyprexa® was originally marketed by Eli Lilly and is now owned by CHEPLAPHARM in many regions.
Notable manufacturers with olanzapine products include Actavis, Glenmark, EG Labo (Eurogenerics), Cipla, Teva and a wide set of generic manufacturers such as Dexcel, Egis, Evolugen and others.
All products are prescription-only (Rx) in major markets and carry regulatory approval from relevant national agencies and the EMA for originator and many generics.
| Brand | Manufacturer | Forms / Dosages |
|---|---|---|
| Zyprexa® | CHEPLAPHARM (originally Eli Lilly) | Tablets 5, 7.5, 10, 15, 20 mg; IM injection |
| Olanzapine Actavis | Actavis Pharma | Tablets 2.5, 5, 7.5, 10, 15, 20 mg |
| Olanzapine Glenmark | Glenmark | Tablets (various strengths) |
| Olanzapine Cipla | Cipla Europe | Tablets (various strengths) |
| Olanzapine ODT | Multiple (e.g., Teva, Abbott) | ODTs 5, 10, 15 mg |
| Other Generics | Dexcel, Egis, Evolugen, Galenicum, others | Tablets, ODTs (pack formats vary) |
Indications And Standard Dosing Regimens
Licensed Indications And Typical Starting Doses
What is olanzapine licensed to treat and how is it usually started?
Olanzapine is licensed for the treatment of schizophrenia and bipolar I disorder (acute mania and maintenance).
Typical adult starting doses for schizophrenia are 5–10 mg once daily, titrated to effect with care taken over sedation.
For acute mania in bipolar disorder, starting doses commonly fall in the 10–15 mg once-daily range, adjusted by clinical response.
The usual maximum recommended daily dose is 20 mg for oral formulations.
Dose adjustments should be individualised and commonly made in 5 mg increments when clinically required.
IM Use And Acute Agitation
How is the intramuscular formulation used in practice?
IM olanzapine is used for acute agitation where rapid control of behaviour is required.
A single 10 mg IM dose is commonly used, with a maximum of 30 mg in 24 hours depending on setting and monitoring.
Titration in the oral setting is usually by 5 mg steps and tailored to the individual.
| Use | Typical Dose | Max Daily Dose |
|---|---|---|
| Schizophrenia (oral) | 5–10 mg once daily (start) | 20 mg/day |
| Bipolar Mania (oral) | 10–15 mg once daily (start) | 20 mg/day |
| Acute Agitation (IM) | 10 mg IM single dose | 30 mg/24 h |
How Olanzapine Works — Mechanism And Pharmacology
Receptor Profile And Clinical Effect
How does olanzapine produce its antipsychotic effects?
Olanzapine is an antagonist at dopamine D2 receptors which contributes to antipsychotic efficacy for positive symptoms.
It also antagonises multiple serotonin receptors, notably 5‑HT2A and 5‑HT2C, which contributes to mood stabilisation and modulation of side-effect profile.
Significant antihistaminergic activity explains sedation, while antimuscarinic effects can cause dry mouth, blurred vision and constipation.
The combined receptor profile underpins both clinical benefits and common adverse effects seen in retail counselling.
Metabolism And Pharmacokinetics
What should pharmacists know about metabolism and important interactions?
Olanzapine is primarily metabolised via CYP1A2 with minor involvement of CYP2D6.
Smoking induces CYP1A2 and can reduce olanzapine plasma concentrations; smoking cessation may lead to increased levels and clinical effects.
The half-life varies with individual factors including age, hepatic function and concomitant medications.
Key practical points: monitor for interaction effects when smoking status changes or when co-prescribing CYP1A2 inhibitors such as fluvoxamine.
| Parameter | Detail |
|---|---|
| Primary Enzyme | CYP1A2 |
| Secondary Enzymes | CYP2D6 (minor) |
| Half-Life | Varies by patient factors (individualised) |
| Renal/Hepatic Notes | Use caution in hepatic impairment; adjust dose and monitor |
Comparative Efficacy And Place In Therapy
Clinical Positioning Versus Other Atypicals
Where does olanzapine sit among atypical antipsychotics?
Olanzapine offers robust efficacy for positive psychotic symptoms and is often compared favourably with risperidone and quetiapine for symptom control.
Clinicians balance this efficacy against a higher risk of metabolic adverse effects relative to aripiprazole or ziprasidone.
Choice of antipsychotic therefore depends on presenting symptoms, metabolic risk profile and prior treatment response.
For patients prioritising rapid and strong symptom control, olanzapine often remains a key option in the formulary despite metabolic trade-offs.
When Clinicians Choose Olanzapine
In which situations is olanzapine preferred?
It is frequently selected when prior agents have failed, when positive symptoms require strong control, or in transitions from inpatient to community care.
Clinicians also consider olanzapine for certain bipolar presentations where mood stabilisation and antimanic efficacy are required.
Monitoring implications include baseline metabolic screening and ongoing review, which should be part of any decision flow weighing efficacy versus metabolic risk.
Side-Effect Profile With Emphasis On Metabolic Risks
Common Adverse Effects Relevant To Retail Counselling
What side effects should the dispensing pharmacist highlight?
Most common effects: weight gain, sedation, dry mouth and constipation.
Other frequent issues: dizziness, orthostatic hypotension and increased appetite.
Counselling points include advice on potential drowsiness and guidance to avoid driving until the effect on alertness is known.
Simple management tips such as dietary advice, regular exercise and proactive management of constipation can be discussed at supply.
Metabolic Syndrome, Monitoring And Mitigation
How should metabolic risk be monitored and managed?
Olanzapine carries a notable risk of metabolic disturbance including hyperglycaemia and dyslipidaemia.
Baseline assessment and ongoing monitoring are essential for safety and long-term health.
| Assessment | Timing | Referral Trigger |
|---|---|---|
| Weight / BMI | Baseline, 3 months, 12 months, annually | Rapid weight gain (>5% in 1 month) or BMI >30 |
| Fasting Glucose / HbA1c | Baseline, 3 months, 12 months, annually | Fasting glucose >7.0 mmol/L or symptomatic hyperglycaemia |
| Lipids | Baseline, 3 months, 12 months, annually | Marked dyslipidaemia requiring GP review |
| BP | Baseline and routine checks | Significant hypertension or orthostatic symptoms |
Contraindications, Warnings And Medico-Legal Points
Absolute And Relative Contraindications
Who must not take olanzapine or needs special caution?
Absolute contraindications include known hypersensitivity to olanzapine or any excipient and patients at imminent risk of acute angle‑closure glaucoma.
Relative contraindications include severe hepatic impairment, prostatic hypertrophy, seizure history and patients with significant cardiovascular disease.
Elderly patients with dementia are at increased risk of stroke and mortality and olanzapine should be avoided where possible.
MHRA And Prescribing Cautions
What documentation and consent considerations matter?
MHRA and NHS guidance emphasise informed consent about metabolic risks and the need for documented baseline assessments.
Prescribers should record rationale for off‑label uses and ensure ongoing monitoring is arranged.
Pharmacy action cues include querying unclear indications, alerting prescribers to missing baseline monitoring and documenting any pharmacist counselling offered.
Drug Interactions And CYP Considerations
Major Pharmacokinetic Interactions
Which drugs and behaviours significantly affect olanzapine levels?
CYP1A2 inducers such as smoking and carbamazepine can reduce olanzapine plasma concentrations and reduce clinical effect.
CYP1A2 inhibitors, notably fluvoxamine, can raise olanzapine levels and increase the risk of adverse effects.
Caution is also required with other sedating medicines, anticholinergics and drugs that prolong the QT interval.
Practical Pharmacy Safeguards
What should a pharmacy team do to reduce interaction risk?
Perform a medication review whenever the GP or specialist alters co‑medication or patients report a smoking status change.
Recommend dose review and extra monitoring if CYP1A2 modulators are started or stopped.
| Interacting Agent | Expected Effect | Pharmacy Action |
|---|---|---|
| Smoking | Reduces olanzapine levels (CYP1A2 induction) | Flag for dose review if smoking stops or starts |
| Fluvoxamine | Increases olanzapine levels (CYP1A2 inhibition) | Advise specialist review; monitor for toxicity |
| Carbamazepine | Reduces olanzapine exposure | Alert prescriber; consider efficacy check |
Special Populations — Children, Elderly, Pregnancy And Hepatic/Renal Impairment
Paediatrics And Adolescents
Is olanzapine suitable for younger patients?
Use in children under 13 years is not typically recommended as safety and efficacy are not established.
Adolescents aged 13–17 may be treated with specialist oversight, lower starting doses and close metabolic monitoring.
Growth, weight and metabolic parameters should be followed closely in any younger patient on olanzapine.
Pregnancy, Breastfeeding, Elderly And Organ Impairment
What dose adjustments and cautions apply to special groups?
Pregnancy requires a careful risk–benefit discussion with the prescriber; data on teratogenicity are limited and neonatal withdrawal or adaptation events are possible.
Breastfeeding decisions should weigh maternal benefit against potential infant exposure.
Elderly patients should start with lower doses (for example, 5 mg daily) because of increased fall, sedation and stroke risk.
Severe liver impairment warrants a lower initial dose and closer monitoring; mild to moderate renal impairment usually requires no routine adjustment but clinical monitoring is advised.
| Population | Practical Dosing Note |
|---|---|
| Children & Adolescents | Not routine <13 yrs; specialist start and monitoring for 13–17 yrs |
| Pregnancy / Breastfeeding | Risk–benefit assessment; monitor neonate if exposure near delivery |
| Elderly | Start low (e.g., 5 mg), titrate cautiously |
| Hepatic Impairment | Lower initial dose; increased monitoring |
Administration, Switching And Missed-Dose Guidance
Oral, ODT And IM Administration Notes
How should different forms be administered safely?
Tablets should be taken at the same time each day to maintain steady effects.
ODTs are helpful for patients with swallowing difficulty and should be allowed to dissolve on the tongue without water unless instructions say otherwise.
IM formulations should only be given by trained staff in appropriate settings due to sedation and cardio‑respiratory monitoring needs.
Advise patients to avoid alcohol and to exercise caution when driving until they know how olanzapine affects them.
Switching Strategies And Missed Dose
What are practical rules for switching or a missed dose?
Switching antipsychotics should generally be guided by a specialist and often involves cross‑titration rather than abrupt substitution to reduce relapse risk.
If a dose is missed, patients should take it as soon as they remember unless the next scheduled dose is close, in which case they should skip the missed dose and not double up.
- Switching checklist: confirm indication, review metabolic monitoring, plan cross‑titration schedule, liaise with prescriber, advise patient of potential transient effects.
Storage, Packaging, Labelling And Supply Chain Considerations
Storage And Transport Requirements
How should olanzapine products be stored in pharmacy and at home?
Store in the original packaging, protected from moisture and light.
Typical recommended storage temperature is room temperature, approximately 15–30°C, avoiding excessive heat or freezing.
Follow any specific storage instructions printed on the pack or patient information leaflet.
Packaging Formats And Supply Availability
What packaging formats are commonly seen in the supply chain?
Tablets are most commonly supplied in blister packs while ODTs are typically in individual foil or plastic pouches.
| Packaging Type | Typical Presentation | Pharmacy Stock Note |
|---|---|---|
| Blister Packs | Tablets in strips of varied counts | Standard stock format for community dispensing |
| Foil Pouches | ODTs usually packaged individually | Preferable for supervised dosing and dysphagia cases |
| Injection Vials/Ampoules | IM injection packaging varies by brand | Usually hospital stock; check local supplier forms |
Common suppliers include CHEPLAPHARM (Zyprexa®), Actavis, Glenmark, Cipla, Teva and multiple generic manufacturers, with regional variations in pack sizes and labelling.
Sourcing, Pricing And NHS Vs Private Dispensing
NHS Prescribing, Exemptions And Cost To Patient
How do UK patients typically receive olanzapine and what do they pay?
Olanzapine is a prescription-only medicine and most patients in the UK receive it via NHS repeat prescriptions with electronic prescribing common.
Prescription charges vary by nation: Scotland, Wales and Northern Ireland offer differing exemptions which can remove the charge for eligible patients.
In England, standard prescription charges apply unless the patient is exempt for age, income or clinical reason.
Private Prescriptions, Online Pharmacies And Pricing Variance
What affects price and patient choice outside the NHS?
Private prescription prices vary by brand and pharmacy chain, with generics generally reducing cost.
Online pharmacies and high-street retailers such as Boots or LloydsPharmacy may offer different delivery options and pricing models.
Verify MHRA registration when using independent online chemists to ensure product authenticity and safe supply.
In our online pharmacy, olanzapine is available without a prescription, with discreet delivery to United Kingdom in 5-14 days.
Pharmacy Product Page Content Essentials (Conversion-Focused)
Required Clinical And Legal Content For A Product Page
What must appear on a compliant product page for olanzapine?
Mandatory elements are the INN (olanzapine), ATC code N05AH03, dosage forms, licensed indications, contraindications, common side effects, storage guidance and manufacturer/distributor information.
Include clear MHRA advice where relevant and a downloadable patient information leaflet to support safe use.
Persuasive But Compliant Copy And Calls To Action
How to balance safety information with effective calls to action?
Use hero bullets that quickly state the indication, starting dose and main warnings, followed by clear stock status and delivery options.
Offer the option for pharmacist consultation, explain NHS prescription process and show trusted payment and delivery messages to build conversion.
- Hero bullets: indication, starting dose, key warnings.
- Conversion elements: consultation booking, NHS prescription upload, next‑day dispatch where available.
Patient Counselling Scripts And Pharmacist Checklists
Brief Pharmacist Script At Dispensing
What to say in two minutes at the counter?
State the medicine name and indication, for example: “This is olanzapine for schizophrenia or bipolar disorder as prescribed.”
Confirm the starting dose and timing, for example: “Take this once daily at the same time each day.”
Highlight key side effects: weight gain, drowsiness, dry mouth and constipation and advise on driving and alcohol.
Mention interactions particularly with smoking and fluvoxamine and arrange follow-up monitoring with the GP or specialist.
Offer printed information and the pharmacist consultation link or contact details.
Clinical Checklist And Referral Triggers
Which baseline checks should be on the pharmacy record?
Checklist: baseline weight/BMI, fasting glucose or HbA1c, lipids, blood pressure and an ECG if clinically indicated.
Referral triggers: new or worsening hyperglycaemia, significant weight gain, extrapyramidal symptoms or severe sedation.
- Attach a checklist card to the patient record and note dates for repeat monitoring.
Practical FAQs, Disposal And Safety Advice
Top Patient FAQs (Short Answers)
Can I drink alcohol while on olanzapine?
No, alcohol increases sedation and should be avoided until you know how the medicine affects you.
Is it safe to drive?
Avoid driving until you know whether olanzapine causes drowsiness or slows your reactions.
Can I stop suddenly?
No, stopping abruptly can risk relapse; consult the prescriber for a withdrawal plan.
Are generics interchangeable?
Switching brands is usually safe but discuss with the pharmacist if you notice any change in effects.
Disposal, Overdose And Emergency Steps
How should unused olanzapine be disposed of?
Return unused or expired medicines to the pharmacy for safe disposal; do not flush them down the toilet.
What to do in an overdose?
Seek emergency medical attention immediately; symptoms of overdose can include profound sedation, delirium, cardiac effects and coma.
Emergency steps: call emergency services, provide details of the medicine and approximate dose, and follow medical instructions.
- Emergency contacts: local ambulance or NHS 111 for urgent advice.
Delivery Across United Kingdom
| City | Region | Delivery time |
|---|---|---|
| London | England | 5-7 days |
| Birmingham | England | 5-7 days |
| Manchester | England | 5-7 days |
| Glasgow | Scotland | 5-7 days |
| Leeds | England | 5-7 days |
| Sheffield | England | 5-7 days |
| Liverpool | England | 5-7 days |
| Edinburgh | Scotland | 5-7 days |
| Bristol | England | 5-7 days |
| Cardiff | Wales | 5-7 days |
| Belfast | Northern Ireland | 5-9 days |
| Plymouth | England | 5-9 days |
| Norwich | England | 5-9 days |
| Coventry | England | 5-9 days |
| Sunderland | England | 5-9 days |
Closing Notes And Practical Next Steps
If you are collecting olanzapine from a pharmacy, bring your prescription and any details of previous antipsychotic treatments.
If you are ordering online, check the product page for the INN, dosage form and manufacturer so you receive the correct olanzapine tablets or ODTs.
For any change in smoking status, new medications such as fluvoxamine, or symptoms suggesting metabolic disturbance, contact the prescribing clinician promptly.
Keep a record of baseline monitoring and bring it to pharmacy consultations to support safe long-term use.
For urgent concerns such as suspected overdose or severe sedation, contact emergency services immediately.
